What Is Amylin? Why It Is Becoming One of the Biggest New Targets in Peptide Research

For several years, GLP-1 dominated metabolic peptide research.

Now another naturally occurring hormone is moving rapidly into the spotlight:

amylin.

Amylin-based drugs are being studied on their own, alongside GLP-1 therapies, alongside GIP/GLP-1 dual agonists, and even experimentally with triple agonists such as retatrutide.

That has made amylin one of the most important emerging pathways in obesity and metabolic-drug development.

A 2026 scientific review specifically described amylin-based therapies as a potential next major class of obesity treatment, with multiple long-acting compounds now in human clinical development. (PubMed⁠)

What Is Amylin?

Amylin is a naturally occurring peptide hormone produced by pancreatic beta cells.

It is released alongside insulin after food is consumed.

Its biological effects include:

• increasing satiety
• promoting meal termination
• slowing gastric emptying
• suppressing post-meal glucagon secretion
• reducing food intake

In simple terms, amylin is one of the body’s natural signals that helps tell the brain:

you’ve eaten enough.

Is Amylin the Same as GLP-1?

No.

They overlap in some of their effects, but they are different hormones acting through different receptor systems.

GLP-1 influences:

• appetite
• insulin secretion
• glucose regulation
• gastric emptying

Amylin also influences:

• satiety
• meal size
• gastric emptying
• glucagon secretion

But the brain circuits and receptor biology involved are not identical.

That is precisely why researchers are interested in combining them.

Why Is Amylin Suddenly Getting So Much Attention?

The success of GLP-1 therapies demonstrated that appetite-regulating hormone pathways can produce large changes in body weight.

Researchers then began asking:

Can another natural satiety pathway provide additional effects without simply increasing GLP-1 activity further?

Amylin became one of the strongest candidates.

The current pipeline now includes compounds such as:

• cagrilintide
• petrelintide
• eloralintide
• zenagamtide
• MET-233i
• ABBV-295
• AZD6234

alongside several combination programmes. (PubMed⁠)

What Was the First Amylin Drug?

The first major proof that amylin biology could be used therapeutically came from pramlintide.

Pramlintide is an amylin analogue that has been used alongside insulin in diabetes.

It demonstrated that pharmacologically reproducing amylin signalling was possible.

But it had limitations.

These included:

• relatively modest weight effects
• frequent injections
• practical complexity

The newer generation of amylin drugs is designed to overcome these limitations by providing much longer duration of action. (PubMed⁠)

What Is Cagrilintide?

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk.

It has attracted particular attention because it is being combined with semaglutide in CagriSema.

Cagrilintide provides amylin-related signalling.

Semaglutide provides GLP-1 signalling.

That means the combination attempts to stimulate two complementary satiety pathways simultaneously.

What Has CagriSema Shown?

CagriSema has now progressed through a very large Phase 3 programme.

In September 2026, Novo Nordisk reported approximately 21% average weight reduction at 68 weeks with CagriSema in the REDEFINE 9 trial. (Novo Nordisk⁠)

The broader Phase 3 programme includes thousands of participants and is evaluating:

• obesity
• type 2 diabetes
• cardiovascular outcomes
• body composition
• weight maintenance

A dedicated cardiovascular-outcomes study includes around 7,000 participants. (Novo Nordisk⁠)

This is important because it moves amylin combination therapy far beyond early experimental research.

What Is Petrelintide?

Petrelintide is another long-acting amylin analogue.

Rather than being developed only as part of a fixed combination, petrelintide is being studied as a standalone once-weekly amylin therapy.

Its Phase 2 programme has now advanced into Phase 3 development for chronic weight management. (Zealand Pharma⁠)

This is scientifically important because it may help answer a major question:

How effective can amylin be without GLP-1?

Why Might Someone Want an Amylin-Only Treatment?

GLP-1 therapies are effective, but not everyone responds or tolerates them in the same way.

An amylin-based therapy may potentially provide:

• a different appetite pathway
• a different gastrointestinal profile
• an alternative for certain patients
• a foundation for combination treatment

Whether these advantages are confirmed clinically remains under investigation.

What Is Eloralintide?

Eloralintide is another emerging amylin therapy, but its design is somewhat different.

Rather than acting as a broad amylin analogue, it is designed to preferentially activate the AMY1 receptor.

Lilly describes it as a selective amylin receptor agonist and is now studying it in Phase 3 trials. (Lilly⁠)

That represents another approach:

instead of trying to mimic all of amylin’s receptor activity, researchers can attempt to target specific amylin receptor subtypes.

Why Might Selective Amylin Signalling Matter?

Different amylin receptor combinations can produce different biological effects.

A more selective agonist could theoretically preserve desirable effects on appetite while changing:

• tolerability
• nausea
• receptor desensitisation
• tissue effects

But whether selective activation is actually better than broader amylin signalling remains an open clinical question.

What Is EloraTZP?

This is where the field becomes particularly interesting.

Lilly is combining eloralintide with tirzepatide.

Tirzepatide activates:

GIP + GLP-1

Eloralintide activates:

amylin signalling

Together, the combination known as EloraTZP targets three nutrient-related hormone pathways:

• amylin
• GIP
• GLP-1

Lilly plans Phase 3 development of this co-formulation. (Lilly⁠)

Why Combine Amylin With Tirzepatide?

Tirzepatide already produces substantial metabolic effects.

Adding amylin provides another satiety signal rather than simply increasing GLP-1 activity.

The theory is:

GLP-1 + GIP

regulate appetite, nutrient handling and glucose,

while

amylin

adds another pathway controlling meal termination and fullness.

That could potentially produce greater weight reduction or different appetite effects.

What Is Zenagamtide?

Zenagamtide, previously known as amycretin, takes yet another approach.

Instead of injecting two different medicines, it combines GLP-1 and amylin activity within a single engineered molecule.

That is known as a unimolecular co-agonist.

A 2026 review reported early clinical weight reductions exceeding 20% with some injectable zenagamtide regimens, although these were earlier-stage data. (PubMed⁠)

This represents an important trend in peptide engineering:

rather than physically combining drugs, scientists can design one molecule that activates multiple pathways.

So What Is the Difference Between These Amylin Strategies?

Researchers are effectively testing several competing designs.

Cagrilintide

Long-acting amylin analogue.

Petrelintide

Long-acting amylin analogue being developed as monotherapy and in combinations.

Eloralintide

Selective AMY1 receptor agonist.

CagriSema

Cagrilintide + semaglutide.

EloraTZP

Eloralintide + tirzepatide.

Zenagamtide

One molecule combining amylin and GLP-1 activity.

The science is no longer asking whether amylin works at all.

It is increasingly asking:

What is the best way to use the pathway?

What About Cagrilintide + Retatrutide?

This represents the next experimental step.

Retatrutide already activates:

• GIP
• GLP-1
• glucagon

Adding cagrilintide introduces amylin-related signalling.

The result is a combination influencing several complementary metabolic receptor systems.

A 2026 animal study found that cagrilintide plus retatrutide produced greater weight and metabolic effects than either compound alone in obese rats.

However, this combination has not been established in human clinical trials.

That distinction is critical.

Why Is Amylin So Interesting Alongside Retatrutide?

Retatrutide already targets several components of metabolism.

But amylin provides something different:

a powerful meal-termination and satiety signal.

In theory, this could create:

• stronger appetite regulation
• smaller meal size
• complementary central nervous system effects
• broader metabolic signalling

But adding more pathways can also increase biological complexity and adverse effects.

Human testing is essential.

Is Amylin Responsible for “Food Noise”?

“Food noise” is a popular informal term rather than a formal scientific diagnosis.

People generally use it to describe persistent or intrusive thoughts about food.

Amylin does influence central pathways involved in:

• satiety
• food intake
• meal termination

So there is a reasonable biological basis for investigating how amylin therapies affect eating behaviour.

But claims that amylin drugs specifically “switch off food noise” should be treated cautiously unless supported by controlled human data.

Could Amylin Be Better for Lean-Mass Preservation?

This is another major area of interest.

When people lose substantial amounts of body weight, some lean tissue is generally lost alongside fat.

Researchers are increasingly evaluating whether different metabolic drugs produce different effects on body composition.

Several amylin development programmes specifically highlight lean-mass preservation as an area requiring further study.

However, it is too early to conclude that amylin therapies universally preserve more muscle than GLP-1-based treatments.

Is Amylin Only About Obesity?

No.

Amylin biology also plays a role in:

• glucose regulation
• pancreatic hormone signalling
• gastric emptying
• post-meal glucagon control

That means amylin-based medicines are also being investigated in people with type 2 diabetes and broader cardiometabolic conditions.

Are Amylin Drugs Peptides?

Yes.

Amylin itself is a peptide hormone.

Most of the leading compounds in development are therefore engineered peptide therapeutics designed to reproduce or selectively modify natural amylin signalling.

This includes long-acting analogues and multi-receptor peptide designs.

Why Are Long-Acting Amylin Peptides So Important?

Natural peptide hormones often have short biological half-lives.

That makes them impractical as medicines unless their duration can be extended.

Modern peptide engineering can modify:

• amino-acid sequences
• albumin binding
• molecular stability
• receptor selectivity
• resistance to enzymatic breakdown

This allows new amylin therapies to be administered weekly rather than several times per day.

That engineering improvement is one reason the field has accelerated so quickly.

Is Amylin Replacing GLP-1?

No.

The current research suggests something more interesting.

Amylin may become complementary to GLP-1 rather than replacing it.

The strongest development programmes increasingly involve:

GLP-1 + amylin

or

GIP + GLP-1 + amylin

rather than choosing one pathway exclusively.

A 2026 review concluded that amylin-based therapies increasingly support a multi-pathway approach to obesity rather than relying on one biological system alone. (PubMed⁠)

Are More Hormone Pathways Always Better?

No.

There is an obvious temptation to think:

one receptor is good,

two are better,

three or five must be even better.

Biology does not work that simply.

Each additional pathway may also introduce:

• additional adverse effects
• receptor interactions
• more complicated dosing
• nutritional consequences
• difficulty balancing the different signals

The future is therefore likely to focus on optimising receptor combinations, not simply maximizing their number.

What Comes After Amylin?

The next generation is already beginning to emerge.

Researchers are increasingly testing:

• selective amylin receptor agonists
• amylin/GLP-1 co-agonists
• amylin + GIP/GLP-1 combinations
• amylin + triple-agonist combinations
• potentially single molecules incorporating even broader receptor activity

That means amylin is becoming part of a much larger transition from single-pathway drugs toward metabolic polypharmacology.

The Bottom Line

Amylin is a naturally occurring peptide hormone released alongside insulin after meals.

Its ability to promote fullness, reduce food intake, slow gastric emptying and regulate post-meal glucagon has made it one of the most important emerging targets in metabolic peptide development.

By 2026, the field had expanded rapidly to include:

• cagrilintide
• petrelintide
• eloralintide
• zenagamtide
• CagriSema
• EloraTZP
• several additional experimental amylin compounds. (PubMed⁠)

The strongest evidence so far suggests that amylin can work both independently and alongside incretin therapies.

CagriSema has already demonstrated the potential of combining amylin and GLP-1 in large Phase 3 programmes, while petrelintide and eloralintide are pushing amylin monotherapy into later-stage development. (Zealand Pharma⁠)

The emerging Cagri + Reta research goes one step further by asking whether amylin can complement triple agonism.

That remains preclinical.

But taken together, the direction of travel is clear:

the future of metabolic peptide research is increasingly moving beyond GLP-1 alone — and amylin is becoming one of the central pathways in that transition.

This article is for research and educational purposes only. Several of the therapies discussed remain investigational, and regulatory status varies by compound and country.